A5101516592- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Esophageal and GI Pathology
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- Medical Imaging Techniques and Applications
- Head and Neck Cancer Studies
- Educational Technology and Pedagogy
- Radiopharmaceutical Chemistry and Applications
- Luminescence Properties of Advanced Materials
- Myasthenia Gravis and Thymoma
- Vascular Tumors and Angiosarcomas
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Salivary Gland Tumors Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Prostate Cancer Diagnosis and Treatment
- Single-cell and spatial transcriptomics
- Tissue Engineering and Regenerative Medicine
Fudan University Shanghai Cancer Center
2015-2025
Fudan University
2014-2024
Shanghai Medical College of Fudan University
2014-2023
Shanghai Clinical Research Center
2023
Charité - Universitätsmedizin Berlin
2017
Renji Hospital
2017
Zhejiang Cancer Hospital
2017
ABSTRACT Cancer progression involves loss of differentiation and acquisition stem cell-like traits, broadly referred to as “stemness”. Here, we test whether the level stemness, assessed by a transcriptome-derived Stemness score, can quantitatively track prostate cancer (PCa) development, progression, therapy resistance, metastasis, plasticity, patient survival. Integrative analysis 3,102 RNA-seq 84,081 microarray samples across 26 datasets reveals progressive increase in decline...
e16035 Background: The efficacy of programmed death receptor 1(PD-1) inhibitors combined with chemotherapy for advanced and metastatic ESCC has been recognized. However, there is limited evidence on the use PD-1 local Primary-recurrent after definitive chemoradiotherapy or radiotherapy, further exploration needed. Methods: This a prospective clinical study. study will focus those who have attained complete response (CR) subsequent to radiotherapy histologically proven in-field recurrence, no...
A phase II study was performed to investigate the efficacy and safety of a 3-week schedule paclitaxel (PTX) plus cisplatin (DDP) combined with concurrent radiotherapy for esophageal squamous cell cancer.Patients newly diagnosed cancer who had histologic proof local-regional carcinoma esophagus, Karnofsky performance status 80 or greater, normal liver, renal, bone marrow functions were enrolled in trial. Chemotherapy consisted DDP (25 mg/m/d) 3 days PTX (175 mg/m) given hours, every weeks 4...
This prospective phase 2 study evaluated the efficacy and safety of intensity modulated radiation therapy plus etoposide/cisplatin (EP) for patients with unresectable thymic epithelial tumors (TETs).Patients limited advanced TETs whose lesions could be encompassed within fields were enrolled in this study. Two cycles EP (75 mg/m2 etoposide 25 cisplatin on days 1-3 29-31) administered concurrently therapy, followed by after therapy. The primary endpoint was objective response rate. secondary...
// Chun-yu Wang 1,* , Jia-ying Deng Xu-wei Cai 2 Xiao-long Fu Yuan Li 3 Xiao-yan Zhou Xiang-hua Wu 4 Xi-chun Hu Min Fan 1 Jia-qing Xiang 5 Ya-wei Zhang Hai-quan Chen Rolando Perez 6 Guo-liang Jiang and Kuai-le Zhao Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Medical College, University, Shanghai, China Chest Hospital, Jiao Tong Pathology, Thoracic Surgery, Center Molecular Immunology, Havana, Cuba * These authors share first authorship Correspondence to: Zhao,...
This study aimed to explore the relationship between irradiation of lymphocyte-related organs at risk (LOARs) and lymphopenia during definitive concurrent chemoradiotherapy (dCCRT) for esophageal squamous cell carcinoma (ESCC).Cases ESCC patients who received dCCRT from 2 prospective clinical trials were identified. To find its correlation with survival outcomes, grades absolute lymphocyte counts (ALCs) nadir radiotherapy recorded following COX analysis. Associations lymphocytes dosimetric...
To evaluate the long-term effectiveness and late toxicities of paclitaxel (PTX) plus cisplatin (DDP) with
Locally advanced esophageal cancer has been treated by a multimodality regimen encompassing combined radiochemotherapy (RCT). The tumor response to neoadjuvant RCT is major determinant of further therapeutic strategies, whether surgery or continuation RCT, and therefore, also the patient's overall prognosis. present study included patients with histologically proven squamous cell carcinoma. C-reactive protein (CRP) level was measured prior following completion RCT. Only CRP measurements...
Abstract Background: Programmed cell death protein 1 (PD-1) inhibitors are approved as second-line (2L) therapy for patients (pts) with ESCC. TMB is a predictive biomarker of response to immune checkpoint blockade in multiple cancers, but its role ESCC unclear. Here, we retrospectively investigated the association between and clinical outcomes phase 3 RATIONALE-302 study anti-PD-1 antibody tislelizumab (TIS) vs investigator-chosen chemotherapy (ICC) 2L treatment advanced...
Abstract Esophageal squamous cell carcinoma (ESCC) stands as one of the most formidable and lethal cancers, necessitating urgent intervention. Despite extensive research efforts to identify optimal radiotherapy chemotherapy strategies, complete response rates remain disappointingly low, challenge swift relapse persists. Previous investigations primarily focused on primary tumors, utilizing single-omics approaches illuminate cellular responses immunotherapy. However, our understanding...
For esophageal squamous cell carcinoma (ESCC), universally accepted pathological criteria for classification by differentiation degree are lacking. Tumor budding, single-cell invasion, and nuclear grade, recognized as prognostic factors in other carcinomas, have rarely been investigated their correlation with prognosis ESCC. This study aims to determine if findings can predict reviewed tumor slides from 326 patients who underwent surgery ESCC between 2007 2012. Tumors were evaluated...
Purpose: The purpose of this study is to the feasibility dosimetric pareto front (PF) prediction based on patient anatomic and parameters for esophagus cancer patients. Methods: Sixty patients in our institution were enrolled study. A total 2920 IMRT plans created generated PF each patient. On average, had 48 plans. features extracted from those mean lung dose (MLD), heart (MHD), spinal cord max PTV homogeneous index (PTVHI) recorded plan. principal component analysis (PCA) was used extract...
4066 Background: Concurrent chemoradiotherapy (CCR) with cisplatin plus 5-Fu (PF) regimen is the standard modality for inoperable locally advanced esophageal squamous cell carcinoma (ESCC) patients. In this phase 3 trial, we aimed to assess efficacy and safety of paclitaxel (TF) versus PF in CCR ESCC Methods: patients presented stage IIa IVa were enrolled a prospective multicenter study. Patients randomized either group or TF group. treated 2 cycles followed by consolidation chemotherapy...